December 21, 2015 - 9:54 a.m.
Kite Pharma Appoints Industry Leader Shawn Cline Tomasello as Chief Commercial Officer
Printer Friendly Version 
December 17, 2015 - 1:06 a.m.
Galapagos and Gilead Announce Global Partnership to Develop Filgotinib for the Treatment of Rheumatoid Arthritis and Other Inflammatory Diseases
Printer Friendly Version 
December 11, 2015 - 10:01 a.m.
Kite Pharma Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
Printer Friendly Version 
December 10, 2015 - 10:13 a.m.
Kite Pharma Announces Pricing of Public Offering of Common Stock
Printer Friendly Version 
December 08, 2015 - 10:15 a.m.
Kite Pharma Announces Proposed Public Offering of Common Stock
Printer Friendly Version 
December 08, 2015 - 7:30 a.m.
Phase 3 Results for Zydelig® With Bendamustine and Rituximab for Relapsed Chronic Lymphocytic Leukemia (CLL) Presented at American Society of Hematology Annual Meeting
Printer Friendly Version 
December 07, 2015 - 10:53 a.m.
Kite Pharma Receives FDA Breakthrough Therapy Designation for KTE-C19 for the Treatment of Refractory, Aggressive Non Hodgkin Lymphoma (NHL)
Printer Friendly Version 
December 07, 2015 - 10:48 a.m.
Kite Pharma Initiates the ZUMA-4 Study to Support Registration of KTE-C19 for Relapsed or Refractory (r/r) Acute Lymphoblastic Leukemia (ALL) in Children and Young Adults
Printer Friendly Version 
December 07, 2015 - 10:23 a.m.
Kite Pharma Presents Phase 1 Results From ZUMA-1 at the 57th American Society of Hematology (ASH) Annual Meeting
Printer Friendly Version 
December 07, 2015 - 10:16 a.m.
Kite Pharma Announces Clinical Biomarker Results of Anti-CD19 CAR T Cell Therapy at the 57th American Society of Hematology Annual Meeting (ASH)
Printer Friendly Version 
December 04, 2015 - 5:29 a.m.
European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Sofosbuvir/Velpatasvir for the Treatment of Hepatitis C
Printer Friendly Version 
December 03, 2015 - 6:11 p.m.
Kite Pharma and GE Global Research Announce Strategic Collaboration to Automate Manufacturing of Engineered T Cell Therapies
Printer Friendly Version 
December 02, 2015 - 6:12 p.m.
Kite Pharma Initiates the ZUMA-3 Study to Support Registration of KTE-C19 for Relapsed or Refractory (r/r) Acute Lymphoblastic Leukemia (ALL) in Adult Subjects
Printer Friendly Version 
November 24, 2015 - 5:01 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences on Tuesday, December 1
Printer Friendly Version 
November 23, 2015 - 6:36 a.m.
European Commission Grants Marketing Authorization for Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for the Treatment of HIV-1 Infection
Printer Friendly Version 
November 16, 2015 - 9:01 a.m.
Gilead’s Zydelig® Combined with Bendamustine and Rituximab Shows Superior Efficacy to Bendamustine/Rituximab in Phase 3 Study of Patients with Relapsed Chronic Lymphocytic Leukemia
Printer Friendly Version 
November 14, 2015 - 9:03 a.m.
Gilead Presents New Data at The Liver Meeting 2015
Printer Friendly Version 
November 14, 2015 - 9:03 a.m.
Multiple Scientific Presentations at The Liver Meeting 2015 Further Highlight the Utility of Sofosbuvir-Based Hepatitis C Therapies
Printer Friendly Version 
November 12, 2015 - 6:14 p.m.
Kite Pharma Reports Third Quarter 2015 Financial Results and Provides Business Update
Printer Friendly Version 
November 12, 2015 - 5:55 p.m.
U.S. FDA Approves New Indications for Harvoni®, Gilead’s Once-Daily Single Tablet Regimen for Chronic Hepatitis C
Printer Friendly Version 
November 09, 2015 - 11:50 a.m.
Kite Pharma Initiates Phase 2 Clinical Study of KTE-C19 (ZUMA-2) in Patients With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL) to Support Registration for a Second Indication
Printer Friendly Version 
November 09, 2015 - 11:46 a.m.
Kite Pharma to Host Third Quarter 2015 Financial Results Conference Call and Webcast
Printer Friendly Version 
November 09, 2015 - 8:32 a.m.
Gilead Sciences to Present at the Credit Suisse 24th Annual Healthcare Conference on Tuesday, November 10
Printer Friendly Version 
November 05, 2015 - 12:48 p.m.
U.S. Food and Drug Administration Approves Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection
Printer Friendly Version 
November 05, 2015 - 12:05 p.m.
Kite Pharma to Present Four Abstracts, including Safety and Efficacy Data from the KTE-C19 Phase 1 Study in Patients with Refractory, Aggressive NHL (ZUMA-1), at the 57th American Society of Hematology Annual Meeting (ASH)
Printer Friendly Version 
November 04, 2015 - 3:02 p.m.
Kite Pharma to Present at Upcoming Investor Conferences in November 2015
Printer Friendly Version 
November 02, 2015 - 3:04 p.m.
Kite Pharma Initiates ZUMA-1 Phase 2 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma (NHL) to Support Registration of KTE-C19
Printer Friendly Version 
October 28, 2015 - 5:53 p.m.
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Sofosbuvir/Velpatasvir for Treatment of All Six Genotypes of Hepatitis C
Printer Friendly Version 
October 27, 2015 - 4:01 p.m.
Gilead Sciences Announces Third Quarter 2015 Financial Results
Printer Friendly Version 
October 27, 2015 - 4:01 p.m.
Gilead Sciences Announces Fourth Quarter 2015 Dividend
Printer Friendly Version 
October 27, 2015 - 3:34 p.m.
Kite Pharma and Alpine Immune Sciences Announce Research Collaboration and License Agreement to Enhance Immune Response in the Tumor Microenvironment
Printer Friendly Version 
October 22, 2015 - 7:34 a.m.
Gilead Announces Phase 3 Results for Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), an Investigational Once-Daily Single Tablet Regimen for HIV
Printer Friendly Version 
October 21, 2015 - 10:02 a.m.
Gilead Provides Update on Investigational Compound, GS-5734, for the Treatment of Ebola Virus Disease
Printer Friendly Version 
October 20, 2015 - 5:01 p.m.
Gilead Sciences to Release Third Quarter 2015 Financial Results on Tuesday, October 27, 2015
Printer Friendly Version 
October 20, 2015 - 3:35 p.m.
Kite Pharma Announces Exclusive License with the National Institutes of Health for T Cell Receptor (TCR)-Based Products to Treat Tumors Expressing MAGE
Printer Friendly Version 
October 15, 2015 - 3:37 p.m.
Kite Pharma Receives Positive Opinions for Orphan Drug Designation in the European Union (EU) for KTE-C19 in Three Additional Hematological Indications
Printer Friendly Version 
October 07, 2015 - 3:38 p.m.
Kite Pharma Commends Steven A. Rosenberg, M.D., Ph.D., on the Prestigious Medal of Honor Award From the American Cancer Society
Printer Friendly Version 
October 02, 2015 - 6:20 p.m.
U.S. Food and Drug Administration Approves New Treatment Combination of Gilead’s Letairis® with Tadalafil for Pulmonary Arterial Hypertension (WHO Group 1)
Printer Friendly Version 
October 01, 2015 - 3:39 p.m.
Kite Pharma Announces Peer-Reviewed Publication of T Cell Receptor Based Product Candidate to Treat HPV-Associated Cancers
Printer Friendly Version 
September 25, 2015 - 7:35 a.m.
European CHMP Adopts Positive Opinion for Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for the Treatment of HIV
Printer Friendly Version 
September 24, 2015 - 3:40 p.m.
Kite Pharma to Present at IBC Life Sciences' IMMUNO-ONCOLOGY: Advancing the Next Generation of Cancer Immunotherapies Conference
Printer Friendly Version 
September 21, 2015 - 8:32 a.m.
Gilead Announces SVR12 Rates from Four Phase 3 Studies Evaluating a Once-Daily, Fixed-Dose Combination of Sofosbuvir (SOF) and Velpatasvir (VEL) (GS-5816) for the Treatment of All Six Hepatitis C Genotypes
Printer Friendly Version 
September 15, 2015 - 5:00 p.m.
Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 16
Printer Friendly Version 
September 15, 2015 - 3:41 p.m.
Franz B. Humer, Former Chairman and CEO of Roche Group, Appointed to Kite Pharma's Board of Directors
Printer Friendly Version 
September 14, 2015 - 3:42 p.m.
Kite Pharma Expands Collaboration With Netherlands Cancer Institute (NKI)
Printer Friendly Version 
September 11, 2015 - 3:43 p.m.
Kite Pharma Receives Positive Opinion for Orphan Drug Designation in the European Union for KTE-C19, Kite's Lead Cancer T-Cell Immunotherapy
Printer Friendly Version 
September 09, 2015 - 8:58 p.m.
Gilead Prices $10 Billion of Senior Unsecured Notes
Printer Friendly Version 
September 08, 2015 - 5:01 p.m.
Gilead Sciences to Present at the Baird 2015 Healthcare Conference on Wednesday, September 9
Printer Friendly Version 
September 03, 2015 - 3:47 p.m.
Kite Pharma to Participate in Upcoming Investor Conferences in September 2015
Printer Friendly Version 
September 03, 2015 - 3:44 p.m.
Kite Pharma Commends Honors Conferred to Scientific Advisory Board Members for Their Significant Contributions to Medicine
Printer Friendly Version 
September 02, 2015 - 8:31 a.m.
Gilead’s Investigational Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide (F/TAF) Meets Primary 48-Week Objective in Phase 3 Study
Printer Friendly Version 
August 26, 2015 - 5:01 p.m.
Results From the AMBITION Study of First-Line Treatment With Letairis and Tadalafil in Pulmonary Arterial Hypertension Published in The New England Journal of Medicine
Printer Friendly Version 
August 20, 2015 - 4:32 p.m.
European Medicines Agency Validates Gilead’s Marketing Application for Single Tablet Regimen Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF) for HIV Treatment
Printer Friendly Version 
August 17, 2015 - 3:52 p.m.
Kite Pharma Provides Update on KTE-C19 Clinical Trial
Printer Friendly Version 
August 14, 2015 - 3:53 p.m.
Kite Pharma to Hold Conference Call to Provide a Corporate Update on Monday, August 17, 2015
Printer Friendly Version 
August 10, 2015 - 4:02 p.m.
Kite Pharma Reports Second Quarter 2015 Financial Results
Printer Friendly Version 
August 06, 2015 - 4:06 p.m.
Kite Pharma to Host Second Quarter 2015 Financial Results Conference Call and Webcast
Printer Friendly Version 
August 05, 2015 - 4:09 p.m.
Kite Pharma to Present at the Canaccord Genuity 35th Annual Growth Conference
Printer Friendly Version 
July 28, 2015 - 4:04 p.m.
Gilead Sciences Announces Third Quarter 2015 Dividend
Printer Friendly Version 
July 28, 2015 - 4:02 p.m.
Gilead Sciences Announces Second Quarter 2015 Financial Results
Printer Friendly Version 
July 27, 2015 - 4:31 p.m.
Gilead Announces Executive Promotions
Printer Friendly Version 
July 21, 2015 - 5:01 p.m.
Gilead Sciences to Release Second Quarter 2015 Financial Results on Tuesday, July 28, 2015
Printer Friendly Version 
July 21, 2015 - 2:08 p.m.
Gilead Announces Phase 3 Results From the First Study to Evaluate Switching From TDF-Based Regimens to a TAF-Based Regimen Containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide (E/C/F/TAF)
Printer Friendly Version 
July 03, 2015 - 2:02 a.m.
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Harvoni®, the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C
Printer Friendly Version 
July 01, 2015 - 4:31 p.m.
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen for HIV Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF)
Printer Friendly Version 
July 01, 2015 - 4:15 p.m.
Kite Pharma and The Leukemia & Lymphoma Society(R) Enter Into Collaboration to Enhance the Development of KTE-C19 in Refractory Aggressive Non-Hodgkin Lymphoma and Launch CAR T-Cell Therapy Educational Programs
Printer Friendly Version 
June 22, 2015 - 4:17 p.m.
Kite Pharma and bluebird bio Announce Strategic Collaboration to Advance Second Generation TCR Cell Therapy Products to Treat HPV-Associated Cancers
Printer Friendly Version 
June 16, 2015 - 4:19 p.m.
Kite Pharma to Host Investor Day on June 23, 2015
Printer Friendly Version 
June 08, 2015 - 5:01 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences on Tuesday, June 9
Printer Friendly Version 
June 02, 2015 - 4:22 p.m.
Kite Pharma Presents Clinical Biomarker Results in Patients Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy at the 2015 ASCO Annual Meeting
Printer Friendly Version 
May 31, 2015 - 9:01 a.m.
Zydelig® in Combination With Ofatumumab Improves Progression-Free Survival in Previously-Treated Patients With Chronic Lymphocytic Leukemia
Printer Friendly Version 
May 29, 2015 - 4:25 p.m.
Kite Pharma to Present Clinical Biomarkers From Patients Treated With Anti-CD19 Chimeric Antigen Receptor T Cell Therapy at the 2015 ASCO Annual Meeting
Printer Friendly Version 
May 28, 2015 - 8:31 a.m.
European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Emtricitabine and Tenofovir Alafenamide for HIV Treatment
Printer Friendly Version 
May 27, 2015 - 5:01 p.m.
Gilead Sciences to Present at the Bernstein 31st Annual Strategic Decisions Conference on Thursday, May 28
Printer Friendly Version 
May 26, 2015 - 4:34 p.m.
Kite Pharma to Present at the Jefferies 2015 Global Healthcare Conference
Printer Friendly Version 
May 21, 2015 - 4:37 p.m.
Kite Pharma Announces That the First Patient in Its Phase 1/2 Clinical Trial Has Been Treated With KTE-C19, Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, for Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)
Printer Friendly Version 
May 18, 2015 - 5:00 p.m.
Gilead Sciences to Present at the UBS 2015 Global Healthcare Conference on Tuesday, May 19
Printer Friendly Version 
May 15, 2015 - 4:38 p.m.
Kite Pharma Reports First Quarter 2015 Financial Results
Printer Friendly Version 
May 12, 2015 - 5:01 p.m.
Gilead Sciences to Present at the Bank of America Merrill Lynch 2015 Health Care Conference on Wednesday, May 13
Printer Friendly Version 
May 12, 2015 - 4:41 p.m.
Kite Pharma to Report First Quarter Financial Results on Friday, May 15, 2015
Printer Friendly Version 
May 06, 2015 - 8:32 a.m.
Gilead Sciences Acquires EpiTherapeutics
Printer Friendly Version 
May 04, 2015 - 4:44 p.m.
Kite Pharma to Participate in Upcoming Investor Conferences in May 2015
Printer Friendly Version 
April 30, 2015 - 4:03 p.m.
Gilead Sciences Declares First Quarterly Cash Dividend
Printer Friendly Version 
April 30, 2015 - 4:02 p.m.
Gilead Sciences Announces First Quarter 2015 Financial Results
Printer Friendly Version 
April 25, 2015 - 1:01 a.m.
Gilead Announces Results From Studies Evaluating Sofosbuvir-Based Regimens in Chronic Hepatitis C Patients With Genotypes 2-5
Printer Friendly Version 
April 23, 2015 - 5:02 p.m.
Gilead Sciences to Release First Quarter 2015 Financial Results on Thursday, April 30, 2015
Printer Friendly Version 
April 23, 2015 - 1:01 a.m.
Gilead’s Harvoni and Sovaldi Demonstrate Efficacy and Safety among Chronic Hepatitis C Patients with Advanced Liver Disease
Printer Friendly Version 
April 23, 2015 - 1:01 a.m.
Gilead Announces Data for Investigational, All-Oral, Pan-Genotypic Three-Drug Regimen of Sofosbuvir, GS-5816 and GS-9857 for Chronic Hepatitis C
Printer Friendly Version 
April 21, 2015 - 4:53 p.m.
Kite Pharma Commends Honors Conferred to Drs. Owen Witte and Steven A. Rosenberg at the 2015 American Association for Cancer Research (AACR) Annual Meeting
Printer Friendly Version 
April 10, 2015 - 5:01 p.m.
Kite Pharma to Present at the 2015 Jefferies Immuno-Oncology Summit in Boston
Printer Friendly Version 
April 07, 2015 - 5:57 p.m.
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide for HIV Treatment
Printer Friendly Version 
April 06, 2015 - 5:04 p.m.
Kite Pharma Announces Publication in Science of Cancer Immunotherapy Articles Authored by Lead Collaborators at the National Cancer Institute and the Netherlands Cancer Institute
Printer Friendly Version 
March 26, 2015 - 5:09 p.m.
Kite Pharma Reports Full-Year and Fourth Quarter 2014 Financial Results
Printer Friendly Version 
March 26, 2015 - 2:00 a.m.
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Sovaldi® (sofosbuvir) for the Treatment of Genotype 2 Chronic Hepatitis C
Printer Friendly Version 
March 25, 2015 - 5:11 p.m.
Kite Pharma to Report Fourth Quarter and Full Year 2014 Financial Results on March 26th, 2015
Printer Friendly Version 
March 17, 2015 - 5:27 p.m.
Kite Pharma Strengthens Its T Cell Receptor (TCR) Cancer Gene Therapy Platform Through Acquisition of T-Cell Factory B.V. (TCF(TM))
Printer Friendly Version 
March 10, 2015 - 5:00 p.m.
Gilead Sciences to Present at the Barclays Global Healthcare Conference on Wednesday, March 11
Printer Friendly Version 
March 06, 2015 - 5:32 p.m.
Kite Pharma to Present at the 2015 Barclays Global Healthcare Conference
Printer Friendly Version 
March 02, 2015 - 5:00 p.m.
Gilead Sciences to Present at the Cowen and Company 35th Annual Health Care Conference on Tuesday, March 3
Printer Friendly Version 
February 27, 2015 - 5:34 p.m.
Kite Pharma Expands Its Research and Development Collaboration With the National Cancer Institute to Develop a Next Generation of Cancer Immunotherapy Products for Solid Tumors
Printer Friendly Version 
February 26, 2015 - 7:06 p.m.
Gilead Announces Phase 3 Results for Investigational Once-Daily Single Tablet HIV Regimen Containing Tenofovir Alafenamide (TAF)
Printer Friendly Version 
February 26, 2015 - 3:16 p.m.
Gilead Announces SVR12 Rates From Phase 3 Study Evaluating Harvoni® for the Treatment of Chronic Hepatitis C in Patients Co-Infected With HIV
Printer Friendly Version 
February 25, 2015 - 3:27 p.m.
Gilead Announces Preclinical Data for an Investigational TLR7 Agonist in SIV-Infected, Virally Suppressed Monkeys
Printer Friendly Version 
February 24, 2015 - 5:02 p.m.
Gilead Sciences to Present at the RBC Capital Markets 2015 Healthcare Conference on Wednesday, February 25
Printer Friendly Version 
February 23, 2015 - 5:36 p.m.
Kite Pharma to Present at the Cowen and Company 35th Annual Health Care Conference
Printer Friendly Version 
February 19, 2015 - 5:38 p.m.
Kite Pharma Establishes Manufacturing Capabilities to Support Development and Commercialization of CAR and TCR Cancer Immunotherapy Products
Printer Friendly Version 
February 09, 2015 - 5:01 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
February 03, 2015 - 5:39 p.m.
Kite Pharma Expands and Strengthens Leadership Team
Printer Friendly Version 
February 03, 2015 - 4:07 p.m.
Gilead Sciences Announces 43 Cents Quarterly Dividend Program and $15 Billion Share Buyback Program
Printer Friendly Version 
February 03, 2015 - 4:07 p.m.
Gilead Sciences Announces Fourth Quarter and Full Year 2014 Financial Results
Printer Friendly Version 
February 02, 2015 - 5:59 p.m.
Kite Pharma to Present at the 17th Annual BIO CEO & Investor Conference
Printer Friendly Version 
January 28, 2015 - 4:31 p.m.
Gilead Announces Executive Promotions
Printer Friendly Version 
January 27, 2015 - 5:01 p.m.
Gilead Sciences to Release Fourth Quarter and Full Year 2014 Financial Results on Tuesday, February 3, 2015
Printer Friendly Version 
January 26, 2015 - 1:01 a.m.
Gilead Expands Hepatitis C Generic Licensing Agreements to Include Investigational Pan-Genotypic Agent
Printer Friendly Version 
January 22, 2015 - 6:00 p.m.
Kite Pharma Announces Expanded Agreement with Tel Aviv Sourasky Medical Center and Pioneering Researcher Professor Zelig Eshhar to Develop Novel Chimeric Antigen Receptor (CAR) Approaches for Cancer Immunotherapy
Printer Friendly Version 
January 19, 2015 - 6:01 p.m.
Kite Pharma Announces Presentations Highlighting Cancer Immunotherapy T Cell Manufacturing Process
Printer Friendly Version 
January 12, 2015 - 5:01 p.m.
Gilead Sciences to Present at the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13
Printer Friendly Version 
January 09, 2015 - 6:02 p.m.
Kite Pharma Expands Senior Management Team With Appointment of Claudine Prowse, Ph.D., as SVP, Corporate Communications and Investor Relations
Printer Friendly Version 
January 08, 2015 - 6:03 p.m.
Kite Pharma Announces Addition of Scott N. Bernstein as Vice President of Intellectual Property Law
Printer Friendly Version 
January 07, 2015 - 6:06 p.m.
Kite Pharma to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Printer Friendly Version 
January 07, 2015 - 6:05 p.m.
Kite Pharma Announces Exclusive License With the National Institutes of Health for T Cell Receptor (TCR)-Based Products to Treat HPV-Associated Cancers
Printer Friendly Version 
January 06, 2015 - 6:06 p.m.
Kite Pharma Granted Orphan Drug Designation in the European Union for KTE-C19, Kite's Lead Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy
Printer Friendly Version 
January 06, 2015 - 8:31 a.m.
Gilead Sciences Announces Acquisition of Phenex Pharmaceuticals’ Development Program for Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Printer Friendly Version 
January 05, 2015 - 6:07 p.m.
Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies
Printer Friendly Version 
NASDAQ (US Dollar)
$72.82
 Stock is Up 0.31 (0.43%)
Data as of 11/22/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh Quote